Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.67 |
| ▸ | NPC1 | O15118 | 2/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 5/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4202749 | 0.90 | SMN1; SMN2 (0.64) | SMN1; SMN2NPC1RAB9ALMNAKDM4E | |
| SCHEMBL4211989 | 0.86 | SMN1; SMN2 (0.63) | SMN1; SMN2NPC1RAB9ALMNAKDM4E | |
| SCHEMBL4206719 | 0.86 | SMN1; SMN2 (0.64) | SMN1; SMN2NPC1RAB9ALMNAKDM4E | |
| SCHEMBL4214986 | 0.84 | SMN1; SMN2 (0.62) | SMN1; SMN2NPC1RAB9ALMNAKDM4E | |
| SCHEMBL4204622 | 0.84 | CYP3A4 (0.64) | SMN1; SMN2NPC1RAB9ALMNAKDM4E | |
| SCHEMBL4201217 | 0.84 | TSHR (0.64) | SMN1; SMN2NPC1RAB9ALMNAKDM4E | |
| SCHEMBL4208429 | 0.81 | SMN1; SMN2 (0.63) | SMN1; SMN2NPC1RAB9ALMNAKDM4E | |
| SCHEMBL4213969 | 0.81 | SMN1; SMN2 (0.57) | SMN1; SMN2NPC1RAB9ALMNAKDM4E | |
| SCHEMBL4211653 | 0.81 | SMN1; SMN2 (0.57) | SMN1; SMN2NPC1RAB9ALMNAKDM4E | |
| SCHEMBL4206983 | 0.80 | SMN1; SMN2 (0.61) | SMN1; SMN2NPC1RAB9ALMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060111348-A1 | Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent for the treatment of metabolic syndrome and related diseases and disorders | NOVO NORDISK A/S (DK) | 2006-05-25 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111348-A1 | Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent for the treatment of metabolic syndrome and related diseases and disorders | HSD11B1, HSD11B2, HSD17B1 | SMN1; SMN2 3473/4885NPC1 412/4885RAB9A 2668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.